Financial Highlights for the Second Quarter of Fiscal 2025 Biomerica continued to deliver improved financial performance, demonstrating revenue growth, disciplined cost management, and progress toward ...

NeurAxis's robust sales growth and disciplined cost management have set the stage for achieving cash flow breakeven in 2026. Notably, recent investments from life science-focused funds have bolstered ...

NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

Utilising a finger-prick blood sample, the PSA test claims to generate ‘accurate’ outcomes within ten minutes.

Report on how AI is redefining market landscape - The global microbiomes market size is estimated to grow by USD 1.13 billion from 2024-2028, according to Technavio. The market is estimated to grow at ...

Peruvian researchers studied a small group of medical students and found that IBS sufferers had a 108% higher prevalence of ED than those without the chronic gastrointestinal disorder.

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for ...

IBS Intelligence (IBSi) is the world’s only pure-play Financial Technology focused research, advisory, and fintech news ...

XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea ...

The United States (US) government’s potential restrictions on artificial intelligence (AI) chip exports will not affect ...

For many years, platinum-based chemotherapy has been one of the mainstays for advanced testicular cancer. Painful peripheral ...